Acrotech Biopharma Company Profile
✉ Email this page to a colleague
What is the competitive landscape for ACROTECH BIOPHARMA, and when can generic versions of ACROTECH BIOPHARMA drugs launch?
ACROTECH BIOPHARMA has five approved drugs.
There are twelve US patents protecting ACROTECH BIOPHARMA drugs.
There are one hundred and seventy-nine patent family members on ACROTECH BIOPHARMA drugs in thirty-four countries and five supplementary protection certificates in four countries.
Summary for Acrotech Biopharma
International Patents: | 179 |
US Patents: | 12 |
Tradenames: | 5 |
Ingredients: | 5 |
NDAs: | 5 |
Drugs and US Patents for Acrotech Biopharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | POWDER;INTRAVENOUS | 020140-001 | Mar 7, 2008 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | |||||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 8,410,077 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 10,040,872 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 9,493,582 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acrotech Biopharma | BELEODAQ | belinostat | POWDER;INTRAVENOUS | 206256-001 | Jul 3, 2014 | RX | Yes | Yes | 8,835,501 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
Acrotech Biopharma | EVOMELA | melphalan hydrochloride | POWDER;INTRAVENOUS | 207155-001 | Mar 10, 2016 | RX | Yes | Yes | 10,940,128 | ⤷ Sign Up | Y | ⤷ Sign Up | |||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for Acrotech Biopharma
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | POWDER;INTRAVENOUS | 020140-001 | Mar 7, 2008 | 6,500,829 | ⤷ Sign Up |
Acrotech Biopharma | FOLOTYN | pralatrexate | SOLUTION;INTRAVENOUS | 022468-002 | Sep 24, 2009 | 6,028,071 | ⤷ Sign Up |
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-003 | Apr 29, 2011 | 6,500,829 | ⤷ Sign Up |
Acrotech Biopharma | FUSILEV | levoleucovorin calcium | SOLUTION;INTRAVENOUS | 020140-002 | Apr 29, 2011 | 6,500,829 | ⤷ Sign Up |
Acrotech Biopharma | FOLOTYN | pralatrexate | SOLUTION;INTRAVENOUS | 022468-001 | Sep 24, 2009 | 6,028,071 | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for ACROTECH BIOPHARMA drugs
Drugname | Dosage | Strength | Tradename | Submissiondate |
---|---|---|---|---|
➤ Subscribe | Injection | 500 mg/vial | ➤ Subscribe | 2018-07-03 |
➤ Subscribe | Injection | 10 mg/mL, 17.5 mL vial and 25 mL vial | ➤ Subscribe | 2011-10-26 |
➤ Subscribe | Injection | 20 mg/mL and 40 mg/2 mL | ➤ Subscribe | 2013-09-24 |
➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | 2017-09-08 |
➤ Subscribe | Injection | 50 mg/vial | ➤ Subscribe | 2013-12-19 |
International Patents for Acrotech Biopharma Drugs
Country | Patent Number | Estimated Expiration |
---|---|---|
Japan | 2009051845 | ⤷ Sign Up |
South Korea | 101189692 | ⤷ Sign Up |
South Korea | 101340824 | ⤷ Sign Up |
Japan | 2018052991 | ⤷ Sign Up |
Japan | 6039721 | ⤷ Sign Up |
Austria | E542527 | ⤷ Sign Up |
>Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Acrotech Biopharma Drugs
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
2701720 | 3/2023 | Austria | ⤷ Sign Up | PRODUCT NAME: MELPHALANFLUFENAMID-HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 (MITTEILUNG) 20220818 |
2701720 | 122023000007 | Germany | ⤷ Sign Up | PRODUCT NAME: MELPHALANFLUFENAMID HYDROCHLORID; REGISTRATION NO/DATE: EU/1/22/1669 20220817 |
2701720 | CR 2022 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
2701720 | CA 2022 00054 | Denmark | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE HYDROCHLORIDE; REG. NO/DATE: EU/1/22/1669 20220818 |
2701720 | 23C1000 | France | ⤷ Sign Up | PRODUCT NAME: MELPHALAN FLUFENAMIDE ET SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, TELS QUE LE CHLORHYDRATE; REGISTRATION NO/DATE: EU/1/22/1669 20220818 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.